ASCO Conference Coverage
Featured Articles
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
Read Article
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
Read Article
Latest Articles
June 25, 2019
June 14, 2019
June 12, 2019
June 12, 2019
June 11, 2019
June 06, 2019
June 06, 2019
June 06, 2019
View More
News Commentary
Editor Image
05 Jun, 2019 | by H. Jack West, MD
While in keeping with what we see informally in our clinics, these documented...
View Comment
Editor Image
01 Jun, 2019 | by Tomasz M. Beer, MD
The TITAN study adds apalutamide to a growing number of agents that improve...
View Comment
View More
OBR Blog
Today, four plenary sessions dropped at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting featured... Read more
June 02, 2019
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019